Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term antiarrhythmic therapy with N-acetylprocainamide.

J J Lertora, A J Atkinson, W Kushner

    Clinical Pharmacology and Therapeutics
    |March 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Common arterial trunk in a cat: a high-resolution morphological analysis with micro-computed tomography.

    Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2021
    Same author

    Measuring Biomarker Progress.

    Clinical pharmacology and therapeutics·2015
    Same author

    Mitochondrial pharmacology: its future is now.

    Clinical pharmacology and therapeutics·2014
    Same author

    In search of physiologically based distribution volume estimates for macromolecules.

    Clinical pharmacology and therapeutics·2012
    Same author

    Models of physiology and physiologically based models in clinical pharmacology.

    Clinical pharmacology and therapeutics·2012
    Same author

    [Hodgkin's disease demonstrated microscopically in the lymph nodes, prostate, kidney, periadrenal tissue, lung, pancreas, liver, and spleen].

    Gastroenterology·2010
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Long-term NAPA therapy reduced premature ventricular contractions (PVCs) and improved cardiac function in patients with chronic PVCs. NAPA therapy was well-tolerated, showing fewer adverse effects than procainamide.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Chronic premature ventricular contractions (PVCs) pose a significant clinical challenge.
    • Previous studies indicated patient response to NAPA therapy during dose-ranging trials.

    Purpose of the Study:

    • To evaluate the long-term effects of NAPA therapy on chronic PVCs.
    • To assess the impact of NAPA on cardiac electrophysiology and left ventricular function.

    Main Methods:

    • A one-year study involving 6 patients with chronic PVCs previously responsive to NAPA.
    • Patients underwent periodic cardiac status evaluations, alternating between NAPA and placebo.
    • Measurements included PVC frequency and pre-ejection period/left ventricular ejection time (PEP/LVET) ratio.

    Main Results:

    Related Experiment Videos

    • One year of NAPA therapy significantly reduced PVC frequency compared to baseline placebo values.
    • The PEP/LVET ratio, initially elevated, normalized after one year of NAPA therapy.
    • NAPA was well-tolerated, with only one patient developing abnormal antinuclear antibody (ANA) titers, unlike procainamide.

    Conclusions:

    • Long-term NAPA therapy is effective in managing chronic PVCs and improving cardiac electrophysiological parameters.
    • The observed effects on PEP/LVET suggest an indirect action of NAPA, potentially related to left ventricular function, rather than a direct inotropic effect.
    • NAPA demonstrates a favorable safety profile compared to procainamide in this patient cohort.